Literature DB >> 22731851

Sequential C-reactive protein measurements in patients with serious infections: does it help?

Suzana Margareth Lobo.   

Abstract

C-reactive protein (CRP) is a marker of inflammation traditionally used as a complementary tool to support the clinical diagnosis and as a marker of severity of disease. CRP is an acute-phase protein synthesized by the liver after stimulus by cytokines and its serum levels increase markedly within hours after the onset of infection, inflammation or tissue injury. Dynamic serial measurement of CRP has been widely used to help therapeutic decision-making. Decreasing plasma concentrations of this biomarker have been used as an indicator for resolution of infection or sepsis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22731851      PMCID: PMC3580631          DOI: 10.1186/CC11347

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


In the previous issue of Critical Care, Coelho and colleagues continued their longstanding work on C-reactive protein (CRP) kinetics by evaluating the patterns of evolution of CRP in patients with severe community-acquired pneumonia (CAP) [1]. A time-dependent analysis was performed and CRP ratios were calculated daily in relation to the CRP concentration on day 0, considered equal to 1. They showed that survivors of CAP had a continuous decrease of the CRP ratio during the first week of antibiotic therapy. On the contrary, the CRP ratio remained elevated in nonsurvivors. A value above 0.5 on day 5 was associated with a fivefold increase in the risk of death in the ICU. These data suggest that persistently elevated CRP values are indicative of poor response to antibiotic therapy in patients with CAP. Serious infections and sepsis demand prompt and appropriate antimicrobial therapy. Many studies have shown the usefulness of serial measurements of CRP as a tool in the follow-up of different conditions such as CAP [2], ventilator-associated pneumonia [3-5], bloodstream infection [6] and sepsis [7,8]. Distinct patterns of CRP kinetics were related to differences in outcomes and/or appropriateness of antibiotic therapy. Ineffective empirical antimicrobial therapy or poor outcome was associated with increases in CRP concentrations in the first 48 to 72 hours in patients with blood-stream infection or sepsis [6-8], or with decreases to ratios <0.4 on the third day in patients with CAP [2] or <0.6 to 0.8 on the fourth day in patients with ventilator-associated pneumonia [3-5]. The kinetics of CRP may be modified by age, genetic variability in the CRP gene, comorbidities, underlying conditions or therapeutic interventions other than antibiotics. The use of CRP or other biomarkers is particularly important in older patients, who may have infection without fever, leucocytosis or other classical signs of infection. In older patients with very high CRP levels, infection was diagnosed in 75% of those with serum concentrations >5.0 mg/dl and in 94% of those with concentrations >10.0 mg/dl [9]. Minor increases in CRP concentrations may, however, represent subclinical illnesses such as cardiovascular diseases, cirrhosis, graft versus host disease, and systemic lupus erythematosus [10-12]. More elevated baseline plasma levels are associated with cancer [13]. In these conditions the persistence of high levels has suggested a complicated course, and a second increase is highly suggestive of an infectious complication. In septic critically ill cancer patients, CRP concentrations are more elevated in those with neutropenia [14]. The incidence of deep venous thrombosis in a group of high-risk ICU patients receiving deep venous thrombosis prophylaxis is about 12% [15]. CRP also increases in patients with deep venous thrombosis. The acute-phase response is induced by the initial formation of thrombus, and a delayed presentation of deep venous thrombosis would allow time for CRP to return to normal levels [16]. Transfusion of blood components is associated with an inflammatory response. Approximately 70% of patients with an ICU length of stay longer than 1 week receive a blood transfusion [17]. A delay in the decline of or no decline in CRP serum levels during the morning following transfusion must therefore be expected [18]. Conversely, some circumstances are expected to lower CRP levels. Glucocorticoids are the most important physiologic inhibitors of inflammation. Patients with acute respiratory distress syndrome treated with methylpredinisolone showed a significant reduction in CRP levels in comparison with those not receiving the drug [19]. CRP is more a marker of severe liver dysfunction than infection in patients with acute hepatic failure. Severe hepatic failure should be ruled out in patients with a high suspicion of infection and an abnormally low CRP concentration or with a marked CRP decline despite persistent septic shock [20]. Hence, failure of CRP levels to fall after 5 days should address additional investigation for inadequate antibiotic therapy, unrevealing resistant infection or localized pus, new infection or serious noninfectious pathology such as thrombosis or cancer. The usefulness of CRP as a surrogate of response to therapy has been widely studied. Use of CRP to guide the duration of antibiotic therapy and the potential of the combination of several bio-markers reflecting different pathophysiological pathways in improving the management of infections remain to be investigated.

Abbreviations

CAP: community-acquired pneumonia; CRP: C-reactive protein.

Competing interests

The author declares that they have no competing interests.
  20 in total

1.  C-reactive protein in rheumatology.

Authors:  I Kushner
Journal:  Arthritis Rheum       Date:  1991-08

2.  Liquid crystal thermography and C reactive protein in the detection of deep venous thrombosis.

Authors:  E A Thomas; M J Cobby; E Rhys Davies; W D Jeans; J T Whicher
Journal:  BMJ       Date:  1989-10-14

3.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

4.  C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study.

Authors:  P Póvoa; L Coelho; E Almeida; A Fernandes; R Mealha; P Moreira; H Sabino
Journal:  Eur Respir J       Date:  2005-05       Impact factor: 16.671

5.  Pilot study evaluating C-reactive protein levels in the assessment of response to treatment of severe bloodstream infection.

Authors:  Pedro Póvoa; Luís Coelho; Eduardo Almeida; Antero Fernandes; Rui Mealha; Pedro Moreira; Henrique Sabino
Journal:  Clin Infect Dis       Date:  2005-04-27       Impact factor: 9.079

6.  The incidence of deep venous thrombosis in ICU patients.

Authors:  P E Marik; L Andrews; B Maini
Journal:  Chest       Date:  1997-03       Impact factor: 9.410

7.  C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia.

Authors:  Thiago Lisboa; Renato Seligman; Emili Diaz; Alejandro Rodriguez; Paulo J Z Teixeira; Jordi Rello
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

8.  Real-time measurement of serum C-reactive protein in the management of infection in the elderly.

Authors:  M L Cox; A G Rudd; R Gallimore; H M Hodkinson; M B Pepys
Journal:  Age Ageing       Date:  1986-09       Impact factor: 10.668

9.  Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.

Authors:  G Umberto Meduri; Emmel Golden; Amado X Freire; Edwin Taylor; Muhammad Zaman; Stephanie J Carson; Mary Gibson; Reba Umberger
Journal:  Chest       Date:  2007-04       Impact factor: 9.410

10.  C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia.

Authors:  Pedro Póvoa; Vicente Ces Souza-Dantas; Márcio Soares; JorgeI F Salluh
Journal:  Crit Care       Date:  2011-05-19       Impact factor: 9.097

View more
  8 in total

Review 1.  Advances in monitoring and management of shock.

Authors:  Haifa Mtaweh; Erin V Trakas; Erik Su; Joseph A Carcillo; Rajesh K Aneja
Journal:  Pediatr Clin North Am       Date:  2013-03-29       Impact factor: 3.278

2.  Serum C-reactive protein concentrations in early abdominal and pulmonary sepsis.

Authors:  Juliane Agustini Orati; Patricia Almeida; Vanessa Santos; Gustavo Ciorla; Suzana Margareth Lobo
Journal:  Rev Bras Ter Intensiva       Date:  2013-03

3.  Correlative study between C-reactive protein, clinical severity, and nerve conduction studies in Guillain-Barrè syndrome.

Authors:  Yosria A Altaweel; Sawsan Abdelaziz; Hala A Fathy; Shimaa AbdelBadea
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2018-04-25

4.  Evaluation of plasma angiopoietin-2 and vascular endothelial growth factor in healthy dogs and dogs with systemic inflammatory response syndrome or sepsis.

Authors:  Maya König; Alice Nentwig; Eliane Marti; Jelena Mirkovitch; Katja-Nicole Adamik; Simone Schuller
Journal:  J Vet Intern Med       Date:  2018-12-21       Impact factor: 3.333

5.  Evaluation of INSTAND e.V.'s external quality assessment for C-reactive protein and procalcitonin.

Authors:  Nathalie Wojtalewicz; Ingo Schellenberg; Klaus-Peter Hunfeld
Journal:  PLoS One       Date:  2019-08-16       Impact factor: 3.240

6.  C-reactive protein velocity discriminates between acute viral and bacterial infections in patients who present with relatively low CRP concentrations.

Authors:  Daniel Bernstein; Dan Coster; Shlomo Berliner; Itzhak Shapira; David Zeltser; Ori Rogowski; Amos Adler; Ora Halutz; Tal Levinson; Omri Ritter; Shani Shenhar-Tsarfaty; Asaf Wasserman
Journal:  BMC Infect Dis       Date:  2021-12-04       Impact factor: 3.090

7.  Clinical chemistry profiles in injection heroin users from Coastal Region, Kenya.

Authors:  Tom Were; Jesca O Wesongah; Elly Munde; Collins Ouma; Titus M Kahiga; Francisca Ongecha-Owuor; James N Kiarie; Aabid A Ahmed; Ernest P Makokha; Valentine Budambula
Journal:  BMC Clin Pathol       Date:  2014-07-09

8.  Maternal genitourinary infections and poor nutritional status increase risk of preterm birth in Gasabo District, Rwanda: a prospective, longitudinal, cohort study.

Authors:  Etienne Nsereko; Aline Uwase; Assumpta Mukabutera; Claude Mambo Muvunyi; Stephen Rulisa; David Ntirushwa; Patricia Moreland; Elizabeth J Corwin; Nicole Santos; Manasse Nzayirambaho; Janet M Wojcicki
Journal:  BMC Pregnancy Childbirth       Date:  2020-06-03       Impact factor: 3.105

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.